Table 2 Lipid profile of patients before initiation of any hypolipidemic treatment

Total cholesterol, mg/dL

(mmol/L)

318 ± 80

(8.2 ± 2.1)

228 ± 75^§

(5.9 ± 1.9)

305 ± 64

(7.9 ± 1.7)

253 ± 98^§

(6.5 ± 2.5)

Triglycerides, mg/dL

(mmol/L)

130 (97–181)

[1.5 (1.1–2.0)]

111 (80–157)^§

[1.3 (0.9–1.8)]^§

68 (59–89)

[0.8 (0.7–1.0)]

111 (80–157)

[1.3 (0.9–1.8)]

HDL-C, mg/dL

(mmol/L)

51 ± 17

(1.3 ± 0.4)

51 ± 17

(1.3 ± 0.4)

57 ± 15

(1.5 ± 0.4)

51 ± 17

(1.3 ± 0.4)

non-HDL-C, mg/dL

(mmol/L)

267 ± 81

(6.9 ± 2.1)

176 ± 75^§

(4.6 ± 1.9)

248 ± 66

(6.4 ± 1.7)

176 ± 75^§

(4.6 ± 1.9)^§

LDL-C_F, mg/dL

(mmol/L)

235 ± 70

(6.1 ± 1.8)

150 ± 71^§

(3.9 ± 1.8)

233 ± 65

(6.0 ± 1.7)

183 ± 97^§

(4.7 ± 2.5)^§

LDL-C_M/H, mg/dL

(mmol/L)

235 ± 69

(6.1 ± 1.8)

151 ± 70^§

(3.9 ± 1.8)

229 ± 65

(5.9 ± 1.7)

180 ± 97^§

(4.7 ± 2.5)^§

^aLDL-C_Lp(a)corM/H, mg/dL

(mmol/L)

211 ± 61

(5.5 ± 1.6)

121 ± 62^†,§

(3.1 ± 1.6)

225 ± 70

(5.8 ± 1.8)

174 ± 94^†,§

(4.5 ± 2.4)^§

^aLp(a), mg/dL

(nmol/L)

21 (9–56)

[42.0 (15.8–118.3)]

20 (9–55)

[42.0 (15.8–118.3)]

15 (8–50)

[28.9 (13.6–105)]

20 (10–60)

[39.8 (18.0–127.0)]

^aApolipoprotein AI, mg/dL

(g/L)

143 ± 35

(1.4 ± 0.4)

144 ± 25

(1.4 ± 0.3)

140 ± 24

(1.4 ± 0.2)

144 ± 25

(1.4 ± 0.3)

^aApolipoprotein B, mg/dL

(g/L)

156 ± 65

(1.6 ± 0.7)

110 ± 35^§

(1.1 ± 0.4)

147 ± 36

(1.5 ± 0.4)

110 ± 35^§

(1.1 ± 0.4)^§